GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study.
Pietrantonio F, Berenato R, Maggi C, Caporale M, Milione M, Perrone F, Tamborini E, Baratti D, Kusamura S, Mariani L, Niger M, Mennitto A, Gloghini A, Bossi I, Settanni G, Busico A, Bagnoli PF, Di Bartolomeo M, Deraco M, de Braud F.
Pietrantonio F, et al. Among authors: mariani l.
J Transl Med. 2016 May 6;14(1):125. doi: 10.1186/s12967-016-0877-x.
J Transl Med. 2016.
PMID: 27154293
Free PMC article.
Clinical Trial.